长非编码RNAIRAIN通过IGF1R-JAK-STAT-BIRC5轴在质瘤中驱动免疫代谢重编程
Ai-Shun Guo1, Hong Lin2, Peng-Wei Lin2
1Department of Neurosurgery, Zhangzhou Municipal Hospital of Fujian Province and Zhangzhou Affiliated Hospital of Fujian Medical University; 1526060316@163.com.
Journal of visualized experiments : JoVE
|December 29, 2025
概括
这项研究确定了一种17基因的免疫代谢特征,用于预测质瘤患者的存活率. 发现长非编码RNAIRAIN通过IGF1R-JAK-STAT-BIRC5通路调节质瘤的免疫和代谢重编程.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 质瘤是一种具有不良预后的侵袭性脑瘤.
- 瘤进展涉及代谢重编程和免疫逃避.
- 识别整合这些过程的分子调节剂对于有效治疗至关重要.
研究的目的:
- 建立基于免疫代谢相关基因 (IMRGs) 的质瘤预后签名.
- 阐明长非编码RNAIRAIN在质瘤免疫代谢中的作用.
- 为了研究质瘤中的IRAIN-IGF1R-JAK-STAT-BIRC5信号通路.
主要方法:
- 来自TCGA,CGGA和GEO队列的转录和临床数据的分析.
- 使用机器学习算法开发一个17基因IMRG预后签名.
- 功能性试验评估IRAIN对质瘤细胞亡,血管生成和免疫细胞透的影响.
主要成果:
- 17基因的IMRG签名准确地预测了多个队伍的整体存活率.
- 过度表达IRAIN抑制了IGF1R-JAK-STAT-BIRC5通路,促进了细胞亡并减少了血管生成.
- 低IRAIN表达与免疫抑制瘤微环境相关.
结论:
- IMRG签名可以作为质瘤的可靠预后工具.
- 艾瑞恩是质瘤免疫代谢重编程的关键调节剂.
- IRAIN-IGF1R-JAK-STAT-BIRC5通路连接免疫和代谢失调,提供潜在的治疗点.
相关概念视频
lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
lncRNA - Long Non-coding RNAs
3.4K
3.4K
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K
Experimental RNAi
7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
RNA Interference
27.7K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.7K

